At the news
? NEUTRALIMPACT 4/10 6-K filed Aug 17, 2026 at 08:05 ET
Evaxion announced a pipeline refocusing, adding a new glioblastoma vaccine program (EVX-05) in collaboration with Duke University while discontinuing the EVX-03 program. The company reiterated its cash runway into H2 2027 and stated EVX-05 costs are within existing budgets, but no financial figures or clinical data were provided. This is a preclinical-stage pipeline update with no near-term revenue or catalyst data.
- New glioblastoma vaccine program EVX-05 announced, off-the-shelf, targeting ERV-derived antigens, in collaboration with Duke University.
- Evaxion maintains cash runway into the second half of 2027; EVX-05 costs are within existing budgets.
- EVX-03 program discontinued.
- No financial figures, clinical data, or guidance were provided in this filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access